<DOC>
	<DOCNO>NCT02508194</DOCNO>
	<brief_summary>This study first assessment efficacy MEDI7510 prevention RSV disease . It also provide estimate vaccine efficacy endpoint incidence placebo arm . It also assess safety immunogenicity concurrent dose MEDI7510 IIV expand observation make Phase 1b study MEDI7510 . It also expand safety database subject dose MEDI7510 . The study also assess immune response MEDI7510 Season 1 Season 2 .</brief_summary>
	<brief_title>A Study Evaluate Efficacy MEDI7510 Older Adults</brief_title>
	<detailed_description>A Phase 2b , double-blind , randomize , control study evaluate efficacy MEDI7510 approximately 1,900 adult subject , globally , 60 year old . Subjects randomize 1:1 ratio receive single intramuscular dose 2 study vaccine contralateral arm : MEDI7510 + IIV placebo + IIV Season 1 . Subjects receive MEDI7510 Northern Hemisphere re-randomized blind Season 2 receive either MEDI7510 + IIV placebo + IIV 1:1 ratio . Clinical efficacy assess Season 2 ; however safety revaccination assess Season 2 .</detailed_description>
	<criteria>Age ≥ 60 year time screen . Medically stable , accord judgment investigator , hospitalization within study period anticipate subject appear likely able remain followup end protocolspecified followup . ( Season 2 ) : Subject receive MEDI7510 IIV Northern Hemisphere Season 1 . History allergy component vaccine . Receipt seasonal influenza vaccine within 6 month prior Season 1 dosing . History allergy intolerance IIV . Pregnancy potential become pregnant study . Females ( 1 ) menstrual period within 12 month prior study enrollment ( 2 ) undergo fertility treatment plan undergo fertility treatment study period exclude . History GuillainBarré syndrome . Previous vaccination RSV . History allergy egg adulthood . History current autoimmune disorder , exception stable , treated hypothyroidism cause autoimmune thyroiditis , acceptable . Immunosuppression cause disease , include human immunodeficiency virus infection ( assessed history ) , medication . Any receipt oral intravenous glucocorticoid therapy within 30 day prior enrollment plan dose within followup period would disqualify . Topical , intranasal , inhale , intraarticular corticosteroid disqualify . Expected need immunosuppressive medication followup period would disqualify . History cancer within precede 5 year treat nonmelanoma skin cancer , locallytreated cervical cancer situ carcinoma breast . Receipt nonstudy vaccine within 28 day prior study dose expect receipt nonstudy vaccine prior Day 29 visit Season 1 . Receipt investigational product 90 day prior randomization expect receipt investigational product period study followup . Receipt immunoglobulins blood product within 4 month study dose ( 120 day ) expect receipt immunoglobulin blood product period study followup . Current bleed clot disorder include use anticoagulant drug antiplatelet activity ( nonsteroidal antiinflammatory drug , clopidogrel , ticagrelor aspirin ) . History alcohol drug abuse psychiatric disorder , opinion investigator , would affect subject 's safety compliance study . ( Season 2 ) : Related Grade 3 4 AE include Grade 3 4 local reaction either MEDI7510 IIV , AESI adjuvanted vaccine , related SAE .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>RSV</keyword>
	<keyword>Older adult</keyword>
	<keyword>MEDI7510</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Efficacy</keyword>
</DOC>